Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

Authors

Daniel Clark Files, Wake Forest University
Frank Tacke, Charite Universitatsmedizin Berlin
Alexandra O'Sullivan, AbbVie
Patrick Dorr, AbbVie
William G. Ferguson, AbbVie
William G. Powderly, Washington University School of Medicine in St. Louis

Journal

PLoS Pathogens

Publication Date

6-1-2022

Volume

18

Issue

6

First Page

e1010547

Document Type

Open Access Publication

DOI

10.1371/journal.ppat.1010547

Rights and Permissions

Files DC, Tacke F, O’Sullivan A, Dorr P, Ferguson WG, et al. (2022) Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLOS Pathogens 18(6): e1010547. https://doi.org/10.1371/journal.ppat.1010547. © 2022 Files et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Files, Daniel Clark; Tacke, Frank; O'Sullivan, Alexandra; Dorr, Patrick; Ferguson, William G.; and Powderly, William G., "Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19." PLoS Pathogens. 18, 6. e1010547 (2022).
https://digitalcommons.wustl.edu/oa_4/81